This filing is routine governance — no immediate trading signal. Monitor for any subsequent M&A activity given the enhanced change-in-control protections, but the adoption of standard severance plans is not a catalyst.
Price Chart
Executive Summary
Tenax Therapeutics amended employment agreements for its CEO, CFO, and CMO to align severance benefits with newly adopted Change in Control and Severance Plans. The amendments provide enhanced severance (12-18 months base salary, bonus, COBRA, and equity acceleration) tied to qualifying terminations. The company also adopted broad-based CIC and Severance Plans for other employees. This is a routine compensation and governance filing with no material financial impact.
Key Facts
- Board approved amendments to employment agreements for CEO Christopher Giordano, CFO Thomas Staab, and CMO Stuart Rich on June 26, 2026.
- CEO Giordano receives 18 months base salary and 18 months COBRA on a change-in-control termination; other executives receive 12 months.
- Non-CIC severance includes 12 months base salary plus up to 12 additional months based on tenure, pro-rated target bonus, and 12 months COBRA.
- Company adopted a Change in Control Plan and a Severance Plan for eligible non-executive employees with double-trigger equity acceleration and cash severance.
- Executive officers are excluded from the new plans and remain covered by individual amended agreements.
Financial Impact
No dollar amounts disclosed; enhanced severance obligations are contingent on future termination events.
Risk Factors
- Enhanced severance could increase cash outflows in a termination scenario, but amounts are not material relative to market cap.
- No financial or operational updates provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-288600 |
| Document: d251626dex103.htm | 0001193125-26-288600 |
| Document: d251626d8k.htm | 0001193125-26-288600 |
| Document: d251626dex102.htm | 0001193125-26-288600 |
| Document: 0001193125-26-288600-index-headers.html | 0001193125-26-288600 |
| Document: 0001193125-26-288600-index.html | 0001193125-26-288600 |
| Document: 0001193125-26-288600.txt | 0001193125-26-288600 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.70 (+24.63%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.70 (+5.94%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.70 (−7.38%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.70 (−9.36%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.70 (−10.79%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.70 (−20.42%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.70 (−7.88%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.70 (+23.27%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.70 (+23.27%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.70 (−87.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers